RT Journal Article
SR Electronic
T1 Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.04.20089904
DO 10.1101/2020.05.04.20089904
A1 Huh, Kyungmin
A1 Ji, Wonjun
A1 Kang, Minsun
A1 Hong, Jinwook
A1 Bae, Gi Hwan
A1 Lee, Rugyeom
A1 Na, Yewon
A1 Choi, Hyoseon
A1 Gong, Seon Yeong
A1 Jung, Jaehun
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.04.20089904.abstract
AB Background Re-purposing of existing drugs for the treatment of COVID-19 might be an effective alternative during the pandemic.Objective To determine the association of the risk of COVID-19 and the drugs which have been suggested to have therapeutic effects against or increase the susceptibility to SARS-CoV-2.Design A case control study using a nationwide claims database. Exposure was defined as a prescription of study drugs which would have been continued until 7 days prior to test for COVID-19 or later.Setting South Korea, where a large testing capacity was available throughout the course of the epidemic.Participants Adults aged 18 years or older who were tested for COVID-19.Measurements The diagnosis of COVID-19.Results Among 65,149 subjects included (mean age, 48.3 years; 49.4% male), 5,172 (7.9%) were diagnosed of COVID-19. Hydroxychloroquine showed no significant association with the risk for COVID-19 (adjusted odds ratio [aOR], 1.48; 95% CI, 0.95–2.31). Camostat (aOR, 0.45; 95% CI, 0.20–1.02) and amiodarone (aOR, 0.54; 95% CI, 0.33–0.89) were associated with a lower risk for COVID-19 in overall population, but the difference did not reach statistical significance in subgroup analysis. Angiotensin receptor blocker was associated with a small increase in the risk (aOR, 1.13; 95% CI, 1.01–1.26), which was not observed in subgroup analysis.Limitations A possibility of bias in the characteristics of controls; information on drug compliance and the severity of underlying conditions could not be obtained.Conclusions No medications included in our study was consistently associated with a risk for COVID-19. These findings suggest that more cautious approach is warranted for the clinical use of re-purposed drugs until the results from clinical trials are available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the Gachon University Gil Medical Center (grant nos. 2018-17 and 2019-11). The sponsor of the study was not involved in the study design, analysis, and interpretation of data; writing of the report; or the decision to submit the study results for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis code is included as a supplement. You can use it freely. Raw data is held by the Korea Health Insurance Review and Assessment Service. You can use it via # opendata4covid19. https://hira-covid19.net/